$ANAB
AnaptysBio Inc

2020 Q4 Form 10-Q Financial Statement

#000137005320000065 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $60.00M $0.00 $0.00
YoY Change 1900.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.090M $4.790M $3.810M
YoY Change 32.9% 25.72% -4.75%
% of Gross Profit
Research & Development $21.57M $19.54M $29.93M
YoY Change 0.65% -34.71% 67.37%
% of Gross Profit
Depreciation & Amortization $140.0K $140.0K $130.0K
YoY Change 0.0% 7.69% 44.44%
% of Gross Profit
Operating Expenses $26.66M $24.34M $33.75M
YoY Change 5.54% -27.88% 54.18%
Operating Profit -$24.34M -$33.75M
YoY Change -27.88% 99.83%
Interest Expense $380.0K $0.00 $240.0K
YoY Change -81.73% -100.0% -40.0%
% of Operating Profit
Other Income/Expense, Net -$80.00K $569.0K $2.661M
YoY Change -27.27% -78.62% 186.44%
Pretax Income $33.65M -$23.77M -$31.08M
YoY Change -265.85% -23.54% 94.79%
Income Tax $0.00 $0.00 -$51.00K
% Of Pretax Income 0.0%
Net Earnings $33.65M -$23.77M -$31.03M
YoY Change -266.09% -23.41% 94.47%
Net Earnings / Revenue 56.08%
Basic Earnings Per Share -$0.87 -$1.15
Diluted Earnings Per Share $1.230M -$0.87 -$1.15
COMMON SHARES
Basic Shares Outstanding 27.35M shares 27.32M shares 27.05M shares
Diluted Shares Outstanding 27.32M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $393.7M $338.3M $421.0M
YoY Change 5.19% -19.63% -14.74%
Cash & Equivalents $250.5M $209.2M $182.9M
Short-Term Investments $143.2M $129.2M $238.1M
Other Short-Term Assets $2.900M $7.500M $3.600M
YoY Change -17.14% 108.33% -10.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $396.6M $345.8M $424.6M
YoY Change 4.98% -18.55% -15.59%
LONG-TERM ASSETS
Property, Plant & Equipment $1.783M $1.585M $1.695M
YoY Change 10.2% -6.49% 26.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.50M $36.20M $23.40M
YoY Change -67.77% 54.7% 25.81%
Other Assets $258.0K $1.114M $1.735M
YoY Change -82.58% -35.79% 2096.2%
Total Long-Term Assets $19.99M $38.94M $26.91M
YoY Change -65.21% 44.7% 33.88%
TOTAL ASSETS
Total Short-Term Assets $396.6M $345.8M $424.6M
Total Long-Term Assets $19.99M $38.94M $26.91M
Total Assets $416.6M $384.8M $451.5M
YoY Change -4.28% -14.78% -13.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.217M $5.484M $10.52M
YoY Change -74.03% -47.88% 70.26%
Accrued Expenses $15.26M $18.14M $15.29M
YoY Change 38.09% 18.66% 113.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $3.100M
YoY Change -100.0% -100.0% -58.67%
Total Short-Term Liabilities $19.82M $24.47M $29.73M
YoY Change -32.89% -17.68% 42.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $33.00K $883.0K
YoY Change -100.0% -96.26% 341.5%
Total Long-Term Liabilities $0.00 $33.00K $883.0K
YoY Change -100.0% -96.26% -66.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.82M $24.47M $29.73M
Total Long-Term Liabilities $0.00 $33.00K $883.0K
Total Liabilities $19.82M $24.51M $30.61M
YoY Change -34.34% -19.95% 30.82%
SHAREHOLDERS EQUITY
Retained Earnings -$264.0M -$297.6M -$223.8M
YoY Change 8.17% 33.0% 72.53%
Common Stock $27.00K $27.00K $27.00K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $396.7M $360.2M $420.9M
YoY Change
Total Liabilities & Shareholders Equity $416.6M $384.8M $451.5M
YoY Change -4.28% -14.78% -13.69%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $33.65M -$23.77M -$31.03M
YoY Change -266.09% -23.41% 94.47%
Depreciation, Depletion And Amortization $140.0K $140.0K $130.0K
YoY Change 0.0% 7.69% 44.44%
Cash From Operating Activities $37.58M -$17.02M -$22.09M
YoY Change -337.7% -22.95% 48.65%
INVESTING ACTIVITIES
Capital Expenditures -$310.0K -$90.00K -$280.0K
YoY Change 181.82% -67.86% -12.5%
Acquisitions
YoY Change
Other Investing Activities $3.900M $4.820M $60.15M
YoY Change -5.8% -91.99% 141.18%
Cash From Investing Activities $3.600M $4.730M $59.87M
YoY Change -10.67% -92.1% 143.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 130.0K 260.0K -1.420M
YoY Change -218.18% -118.31% -100.63%
NET CHANGE
Cash From Operating Activities 37.58M -17.02M -22.09M
Cash From Investing Activities 3.600M 4.730M 59.87M
Cash From Financing Activities 130.0K 260.0K -1.420M
Net Change In Cash 41.31M -12.03M 36.36M
YoY Change -447.43% -133.09% -84.62%
FREE CASH FLOW
Cash From Operating Activities $37.58M -$17.02M -$22.09M
Capital Expenditures -$310.0K -$90.00K -$280.0K
Free Cash Flow $37.89M -$16.93M -$21.81M
YoY Change -341.34% -22.38% 50.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001370053
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37985
dei Entity Registrant Name
EntityRegistrantName
ANAPTYSBIO, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3828755
dei Entity Address Address Line1
EntityAddressAddressLine1
10421 Pacific Center Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
362-6295
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
ANAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27347805 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
209154000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
171017000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
129192000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
203210000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7468000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3506000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
345814000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
377733000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1585000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1618000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
36177000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
54305000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1114000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1481000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
60000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
60000 USD
CY2020Q3 us-gaap Assets
Assets
384750000 USD
CY2019Q4 us-gaap Assets
Assets
435197000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5484000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16237000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18139000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11052000 USD
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1375000 USD
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
851000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
871000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24474000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29535000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
654000 USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27346000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27346000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27255000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27255000 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
657560000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
648669000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
259000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
338000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297603000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244026000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
360243000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
405008000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
384750000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
435197000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15000000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5000000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19542000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29931000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58458000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77912000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4794000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3814000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13766000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12262000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
24336000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
33745000 USD
us-gaap Operating Expenses
OperatingExpenses
72224000 USD
us-gaap Operating Expenses
OperatingExpenses
90174000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24336000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33745000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-57224000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-85174000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
0 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
240000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
427000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
841000 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
625000 USD
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2757000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3583000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8702000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
144000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
64000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
110000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
569000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2661000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3647000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7971000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-23767000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31084000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-53577000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-77203000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-51000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-130000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-23767000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-31033000 USD
us-gaap Net Income Loss
NetIncomeLoss
-53577000 USD
us-gaap Net Income Loss
NetIncomeLoss
-77073000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-25000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
189000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-494000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-94000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-79000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
703000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24261000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31127000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53656000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76370000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.85
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27316000 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27058000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27286000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27022000 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
405008000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2975000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
807000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8262000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
400564000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
71000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2741000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-392000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-21548000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
381436000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
263000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2805000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-494000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-23767000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
360243000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
486365000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
574000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2867000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-22078000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
468155000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3643000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
370000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23962000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
448421000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
454000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3144000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-94000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-31033000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
420892000 USD
us-gaap Net Income Loss
NetIncomeLoss
-53577000 USD
us-gaap Net Income Loss
NetIncomeLoss
-77073000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
415000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
374000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4431000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13180000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51735000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
8521000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
9654000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-239000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2449000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-503000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2902000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2099000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53712000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
156572000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
175049000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
247707000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
303146000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
258000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
701000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
90877000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
127396000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
370000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1243000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1375000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5625000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1005000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4382000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38137000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
69302000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171077000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113656000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
209214000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
182958000 USD
us-gaap Interest Paid Net
InterestPaidNet
4000 USD
us-gaap Interest Paid Net
InterestPaidNet
384000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
165000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
82000 USD
us-gaap Nature Of Operations
NatureOfOperations
Description of the Business <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div>
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6662000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6297000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5077000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4679000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1585000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1618000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2782000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2152000 USD
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1039000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
435000 USD
CY2020Q3 anab Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14094000 USD
CY2019Q4 anab Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
8196000 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
224000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
269000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18139000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11052000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
39317000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
14000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
164902000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
481000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
165369000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
39317000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
14000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
23594000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
23594000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
6000 USD
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27346228 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27346228 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2876063 shares
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6913830 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3039880 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
461425 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.30
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
91146 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
534096 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
37.54
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2876063 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6747000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1355530 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M20D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6365000 USD
CY2020Q3 anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
2805000 USD
CY2019Q3 anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
3144000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
8521000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
9654000 USD
CY2020Q3 anab Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Not Yet Recognized Stock Options
EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions
24800000 USD
anab Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognized Period For Recognition
EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition
P3Y10D
anab Lessee Operating Lease Number
LesseeOperatingLeaseNumber
2 lease
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P1Y
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0859
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
824000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1402000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
851000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
871000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
654000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
660000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
660000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
722000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
698000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
247000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
676000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2020Q3 anab Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
923000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
39000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
884000 USD
CY2020Q3 us-gaap Prepaid Rent
PrepaidRent
200000 USD
CY2020Q3 us-gaap Security Deposit
SecurityDeposit
300000 USD

Files In Submission

Name View Source Status
0001370053-20-000065-index-headers.html Edgar Link pending
0001370053-20-000065-index.html Edgar Link pending
0001370053-20-000065.txt Edgar Link pending
0001370053-20-000065-xbrl.zip Edgar Link pending
anab-20200930.htm Edgar Link pending
anab-20200930.xsd Edgar Link pending
anab-20200930_cal.xml Edgar Link unprocessable
anab-20200930_def.xml Edgar Link unprocessable
anab-20200930_g1.jpg Edgar Link pending
anab-20200930_htm.xml Edgar Link completed
anab-20200930_lab.xml Edgar Link unprocessable
anab-20200930_pre.xml Edgar Link unprocessable
anab-93020x10qxexx311.htm Edgar Link pending
anab-93020x10qxexx312.htm Edgar Link pending
anab-93020x10qxexx321.htm Edgar Link pending
anab-93020x10qxexx322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lizzulemploymentagreem.htm Edgar Link pending
loumeauamendedandresta.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mulroyemploymentagreem.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending